Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 21

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 21
---
 we cannot predict the nature, scope,
or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws
might be administered or interpreted.

We
are also subject to other laws and regulations governing our international operations, including regulations administered by the government
of the U.S. and other countries in which we operate or plan to operate, including applicable export control regulations, economic sanctions
on countries and persons, customs requirements, and currency exchange regulations, (collectively referred to as the “Trade Control
laws”).

However,
there is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including
the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the FCPA and other anti-corruption
laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures,
and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity, as
well as our reputation. Likewise, any investigation of any potential violations of the FCPA, other anti-corruption laws or Trade Control
laws by the U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial
condition.

Our
proprietary information, or that of our suppliers and business partners, may be lost or we may suffer security breaches.

In
the ordinary course of our business, we will collect and store sensitive data, including valuable and commercially sensitive intellectual
property, clinical trial data, our proprietary business information and that of our suppliers and business partners, and personally identifiable
information of our clinical trial subjects and employees, on our networks, and with our third-party cloud service providers. The secure
processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information
technology and infrastructure, and that of our third parties, may be vulnerable to attacks by hackers or breached due to employee error,
malfeasance, or other disruptions. Any breach could compromise our networks and the information stored there could be accessed, publicly
disclosed, lost, or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability
under laws that protect the privacy of personal information, regulatory penalties, disrupt our operations, damage our reputation, and
cause a loss of confidence in our products and our ability to conduct clinical